IN THE SPOTLIGHT

ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis

ctDNA clearance predicts survival in unresectable EGFR-mutant NSCLC: a meta-analysis

Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China

Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

Redefining the Frontline, Reframing the Second Line, and Recalibrating Risk-Benefit Assessments in EGFR-Mutant NSCLC

Redefining the Frontline, Reframing the Second Line, and Recalibrating Risk-Benefit Assessments in EGFR-Mutant NSCLC

Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function

Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function

Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis

Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research